公开(公告)号：US20220135532A1

公开(公告)日：2022-05-05

申请号：US17572037

申请日：2022-01-10

Applicant: Reneo Pharmaceuticals, Inc.

Inventor： Susana DEL RIO GANCEDO ,  Osama SULEIMAN ,  Emma SHARP ,  Cristina BALOGH ,  Rachael LEE ,  Julie MACRAE ,  Neil FEEDER

IPC: C07D295/096 ,  A61K9/00 ,  A61K9/08 ,  A61K9/20 ,  A61K9/48

Abstract: Described herein is crystalline sodium (E)-2-(4-((3-(4-fluorophenyl)-3-(4-(3-morpholinoprop-1-yn-1-yl)phenyl)allyl)oxy)-2-methylphenoxy)acetate, uses of such crystalline material in the preparation of pharmaceutical compositions for the treatment of diseases or conditions that would benefit by administration with a PPARδ agonist compound.

公开(公告)号：US20220024888A1

公开(公告)日：2022-01-27

申请号：US17381005

申请日：2021-07-20

Applicant: Reneo Pharmaceuticals, Inc.

Inventor： Susana DEL RIO GANCEDO ,  Osama SULEIMAN ,  Emma SHARP ,  Cristina BALOGH ,  Rachael LEE ,  Julie MACRAE ,  Neil FEEDER

IPC: C07D295/096 ,  A61K9/00 ,  A61K9/08 ,  A61K9/20 ,  A61K9/48

Abstract: Described herein is crystalline sodium (E)-2-(4-((3-(4-fluorophenyl)-3-(4-(3-morpholinoprop-1-yn-1-yl)phenyl)allyl)oxy)-2-methylphenoxy)acetate, uses of such crystalline material in the preparation of pharmaceutical compositions for the treatment of diseases or conditions that would benefit by administration with a PPARδ agonist compound.

公开(公告)号：US20240002356A1

公开(公告)日：2024-01-04

申请号：US18333454

申请日：2023-06-12

Applicant: Reneo Pharmaceuticals, Inc.

Inventor： Susana DEL RIO GANCEDO ,  Osama SULEIMAN ,  Emma SHARP ,  Cristina BALOGH ,  Rachael LEE ,  Julie MACRAE ,  Neil FEEDER

IPC: C07D295/096 ,  A61K9/00 ,  A61K9/08 ,  A61K9/20 ,  A61K9/48

CPC classification number: C07D295/096 ,  A61K9/0019 ,  A61K9/08 ,  A61K9/2054 ,  A61K9/4825 ,  A61K9/4866 ,  A61K9/0053 ,  C07B2200/13

Abstract: Described herein is crystalline sodium (E)-2-(4-((3-(4-fluorophenyl)-3-(4-(3-morpholinoprop-1-yn-1-yl)phenyl)allyl)oxy)-2-methylphenoxy)acetate, uses of such crystalline material in the preparation of pharmaceutical compositions for the treatment of diseases or conditions that would benefit by administration with a PPARS agonist compound.